<![CDATA[Samsung Bioepis Co., Ltd. 보도자료 - 뉴스와이어]]>https://www.newswire.co.kr/?md=A10&act=article&no=48187>Wed, 29 Apr 2026 18:25:01 +0900Copyright (c) 2004~2026 Korea Newswire All rights reservedko-KR<![CDATA[Samsung Bioepis and ATLATL Sign Memorandum of Understanding (MoU) to Accelerate Early-Stage Biotech Innovation in Asia-Pacific]]>https://www.newswire.co.kr/newsRead.php?no=1033441Wed, 29 Apr 2026 13:13:14 +0900<![CDATA[Samsung Bioepis Initiates Phase 1 Clinical Trial for SBE303, Nectin-4 Targeting Antibody-Drug Conjugate (ADC) Candidate]]>https://www.newswire.co.kr/newsRead.php?no=1032354Wed, 15 Apr 2026 08:40:38 +0900<![CDATA[Samsung Bioepis Enters into Partnership Agreement with Sandoz for Up to Five Next-Generation Biosimilar Candidates]]>https://www.newswire.co.kr/newsRead.php?no=1030583Wed, 18 Mar 2026 16:38:34 +0900<![CDATA[Samsung Bioepis and Epis NexLab Sign Research Collaboration and License Agreement with G2GBIO to Develop Novel Assets Including Long-acting Semaglutide]]>https://www.newswire.co.kr/newsRead.php?no=1030335Mon, 16 Mar 2026 09:23:52 +0900<![CDATA[Samsung Bioepis Announces Approval of Ustekinumab Biosimilar in Japan]]>https://www.newswire.co.kr/newsRead.php?no=1025898Tue, 23 Dec 2025 09:07:33 +0900<![CDATA[Samsung Bioepis And Phrontline Announce a Global Strategic Partnership to Advance Best-in-Class Antibody-Drug Conjugate Therapeutics for Solid Tumors]]>https://www.newswire.co.kr/newsRead.php?no=1020990Tue, 21 Oct 2025 09:45:27 +0900<![CDATA[Samsung Bioepis Enters into a Strategic Partnership with NIPRO for Commercialization of Multiple Biosimilars in Japan]]>https://www.newswire.co.kr/newsRead.php?no=1012699Mon, 09 Jun 2025 11:44:42 +0900